Generic Vigamox Availability

Vigamox is a brand name of moxifloxacin ophthalmic, approved by the FDA in the following formulation(s):

VIGAMOX (moxifloxacin hydrochloride - solution/drops;ophthalmic)

  • Manufacturer: ALCON PHARMS LTD
    Approval date: April 15, 2003
    Strength(s): EQ 0.5% BASE [RLD]

Has a generic version of Vigamox been approved?

No. There is currently no therapeutically equivalent version of Vigamox available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vigamox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
    Patent 5,607,942
    Issued: March 4, 1997
    Inventor(s): Petersen; Uwe & Schenke; Thomas & Krebs; Andreas & Grohe; Klaus & Schriewer; Michael & Haller; Ingo & Metzger; Karl G. & Endermann; Rainer & Zeiler; Hans-Joachim
    Assignee(s): Bayer Aktiengesellschaft
    7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives, of the formula ##STR1## in which X.sup.1 is halogen, X.sup.2 is hydrogen, halogen, amino or other radical, R.sup.1 is alkyl, cycloalkyl, optionally substituted phenyl or other radical, R.sup.2 is hydrogen, alkyl or a dioxolylmethyl radical, R.sup.3 is ##STR2## and A is N, CH, C-halogen, or the like, or forms a bridge with R.sup.1, and addition products thereof.
    Patent expiration dates:
    • March 4, 2014
      ✓ 
      Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • September 4, 2014
      ✓ 
      Pediatric exclusivity
  • Ophthalmic antibiotic compositions containing moxifloxacin
    Patent 6,716,830
    Issued: April 6, 2004
    Inventor(s): Gerald; Cagle & Robert L.; Abshire & David W.; Stroman & John M.; Yanni
    Assignee(s): Alcon, Inc.
    Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Patent expiration dates:
    • September 29, 2019
      ✓ 
      Drug product
    • March 29, 2020
      ✓ 
      Pediatric exclusivity
  • Method of treating ophthalmic infections with moxifloxacin compositions
    Patent 7,671,070
    Issued: March 2, 2010
    Inventor(s): Cagle; Gerald & Abshire; Robert L. & Stroman; David W. & Yanni; John M.
    Assignee(s): Alcon, Inc.
    Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Patent expiration dates:
    • September 29, 2019
      ✓ 
      Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
    • March 29, 2020
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)